Clinical Trial eConsent Platform Vendor Security Risk Assessment Guide
Which vendor security controls should a clinical trial eConsent assessment cover?
A clinical trial eConsent platform handles more than signed forms. It may process participant identity details, consent materials and versions, electronic signatures, and records of the consent process. Assess how the vendor protects the confidentiality, integrity, availability, and traceability of those records across the platform and its service providers.
Start by defining the platform’s intended use, the records it creates or maintains, the parties that access them, and the regulations and sponsor requirements relevant to your study. FDA’s guidance explains that applicable requirements depend on the records and processes involved; using electronic records and electronic signatures does not, by itself, make every system subject to every Part 11 provision. Review the FDA guidance on electronic systems, records, and signatures in clinical investigations and its eConsent guidance when determining the expectations for your use case.
- Security governance: Request the vendor’s security policies, risk-management approach, incident response process, workforce training practices, and process for reporting incidents that could affect study data or participant privacy.
- Identity and access: Evaluate role-based access control, unique user accounts, multifactor authentication options, account provisioning and removal, and periodic access reviews.
- Data protection: Review safeguards for personally identifiable information, encryption in transit and at rest, key management, backups, and data segregation between customers.
- System integrity: Check audit trail integrity, change management, security monitoring, vulnerability management, and system validation documentation appropriate to the platform’s intended use.
- Service-provider oversight: Identify hosting providers and other subprocessors that may handle study data, where they process it, and how the vendor oversees their security and continuity controls.
- Recovery and exit: Confirm how records can be accessed, exported, retained, or transferred if the platform is unavailable, the contract ends, or the vendor stops providing the service.
Do not treat a vendor’s security certification, assessment report, or completed questionnaire as proof that your organization or study is compliant. Assess the evidence against your own documented risks, study requirements, agreements, and responsibilities.
How should access controls and authentication be evaluated?
Ask the vendor to demonstrate how it limits access to authorized users and how permissions are assigned, changed, reviewed, and revoked. Role-based access control should reflect actual responsibilities—for example, a participant, investigator, site coordinator, sponsor monitor, and vendor support user should not automatically receive the same access.
Check whether accounts are individually attributable rather than shared, whether privileged or support access is restricted and monitored, and whether temporary access expires. Ask how the platform handles failed logins, session timeouts, account lockouts, and user departures. Evaluate multifactor authentication for staff and administrators, including whether it can be required by your organization’s policy. Treat MFA as a control to assess in context rather than assuming a specific MFA method is a universal federal requirement.
Request a sample user-role matrix, a description of account lifecycle procedures, and evidence of a recent access review. FDA’s current clinical-investigation guidance recommends that sponsors maintain records of authorized users, their roles, and their access permissions. The FDA’s E6(R3) Good Clinical Practice guidance also addresses user management and access controls for computerized systems.
If the platform handles electronic protected health information for a covered entity or business associate, determine whether HIPAA applies to the relevant parties and data flows. The HIPAA Security Rule requires regulated entities to implement appropriate safeguards, including access controls and authentication; it does not make every vendor or every clinical-trial record automatically subject to HIPAA. See the HHS summary of the HIPAA Security Rule.
How are consent records stored, transferred, and protected?
Map the full record lifecycle: what information the platform collects, where it is stored, how it moves between the participant, site, sponsor, and other systems, and what happens when it is exported or archived. Include consent form versions, materials presented during the process, signature information, timestamps, and records needed to reconstruct the consent event.
Ask the vendor to describe encryption in transit and at rest, its key-management approach, backup protections, and safeguards against unauthorized access or alteration. Verify how it protects data moving through integrations, email or messaging workflows, and downloads—not just data stored in the primary database. Request a current data-flow diagram and clarify the parties responsible for each transfer.
Discuss data residency directly: identify hosting regions, locations where support staff may access data, subprocessors, and any cross-border transfers. Do not assume a particular country or region is required by a universal eConsent rule; determine the applicable legal, contractual, institutional, and sponsor requirements for your study. Ask how the vendor notifies customers about changes to hosting locations or subprocessors.
Confirm how the platform prevents records from being silently overwritten and how it preserves prior versions. FDA’s eConsent guidance describes eConsent data as including the consent versions and materials presented, relevant amendments, and the participant’s or legally authorized representative’s electronic signature and signing date. It also recommends that subjects receive a copy of the signed consent form with the signing date. Review the FDA eConsent guidance and confirm how the platform supports these records and the applicable consent process.
Where HIPAA applies, HHS identifies transmission security as a technical safeguard for electronic protected health information. Ask the vendor how its safeguards address the confidentiality and integrity of information during transmission, and document how its controls fit with your organization’s responsibilities. The HHS HIPAA Security Rule summary explains the relevant safeguard standards.
Ready to assess your HIPAA security risks?
Join thousands of organizations that use Accountable to identify and fix their security gaps.
Take the Free Risk AssessmentWhat should audit trails capture and how should records be archived?
An audit trail should let an authorized reviewer reconstruct significant activity affecting a consent record. Ask the vendor to show how the system captures record creation, changes, corrections, and deletion, including who performed the action, when it occurred, and the prior and new values where applicable. For changes, ask whether the reason is recorded when appropriate and whether the system preserves the original information.
Review whether audit trails are protected from alteration or disabling, can be searched and exported in a usable format, and can be linked to the associated participant and consent record. Consider whether access events, administrative actions, signature events, consent-form versions, and relevant workflow steps are captured in a way that supports the study’s oversight and inspection needs.
FDA’s 2024 guidance says audit trails for electronic records should capture changes, identify the individuals making them, and record the date and time; it also recommends including reasons for changes when applicable. It describes protecting audit trails from modification or being disabled and retaining them for at least as long as the associated electronic records. See the FDA guidance on electronic systems, records, signatures, and audit trails.
Ask for the vendor’s retention, archiving, retrieval, and destruction procedures. Confirm that your organization can retrieve complete records—including audit trails and relevant consent materials—in a readable, exportable format for the required retention period. Retention periods depend on the applicable study and regulatory requirements, so define them with the sponsor and study team rather than relying on a vendor’s default setting.
FDA’s clinical-trial computerized-systems guidance emphasizes that records must remain retrievable and that migration to a new system should preserve complete and accurate study data and related information, including audit trails. Request the vendor’s archive and migration approach, and ask how it verifies records after export or transfer. See the FDA guidance on computerized systems used in clinical trials.
What vendor documentation and system validation evidence should be requested?
Request documentation proportionate to the platform’s intended use and the significance of the records it manages. A useful review package may include:
- A system overview, intended-use description, data-flow diagram, and list of relevant interfaces and subprocessors.
- Security policies or summaries covering access management, incident handling, vulnerability management, backup, recovery, and change control.
- System validation documentation, including requirements, risk assessment, test approach, test results, and procedures for managing defects and changes.
- Documentation describing electronic signatures, audit-trail behavior, record export, retention, and archiving.
- Available independent security assessment reports or certifications, with the assessment scope, period covered, exceptions, and remediation status clearly identified.
- Service agreements that define security responsibilities, incident notification, data return or deletion, retention support, and service continuity.
Ask for evidence that the system was tested for its intended use, not simply a general claim that it is “validated.” Review how the vendor controls software releases, evaluates changes, communicates defects, and assesses the impact of updates on study configuration and records. FDA guidance states that sponsors should have suitable validation and computerized-system controls in place, proportionate to the system’s importance and the data or activities it handles. See the FDA E6(R3) Good Clinical Practice guidance.
Request enough detail to assess the system without assuming that all vendor security documents must be disclosed in full. HHS notes that HIPAA does not expressly require a cloud service provider to give a customer documentation of its security practices or permit a customer audit. Where applicable, address evidence access, audit rights, and cooperation in the contract and assess what the vendor can provide. See HHS guidance on HIPAA and cloud computing.
Part 11 applicability depends on whether electronic records are maintained or submitted to meet FDA recordkeeping or submission requirements. A vendor’s statement that its product is “Part 11 compliant” is not a substitute for evaluating the records, intended use, configuration, procedures, and responsibilities in your specific study. The FDA Part 11 Scope and Application guidance explains the agency’s approach.
How should platform oversight, maintenance, and downtime alternatives be assessed?
Clarify which party is responsible for system administration, security monitoring, incident response, backups, recovery, configuration, and study-level oversight. Ask how the vendor notifies sponsors of security incidents, service interruptions, defects, and material system changes, and how it supports investigations and corrective actions. Define notification timelines and escalation contacts in the agreement and study procedures.
Review maintenance and release practices, including advance notice, testing, rollback plans, and the process for identifying effects on consent templates, signatures, records, and integrations. Ask how the vendor evaluates vulnerabilities, tracks remediation, and communicates unresolved issues that could affect confidentiality, integrity, availability, or study conduct.
Request the business continuity and disaster recovery approach, including backup frequency, recovery objectives, restoration testing, and customer communications during an outage. Ask the vendor to demonstrate how users can retrieve records after service is restored and how missing or interrupted consent activity is identified and reconciled.
Agree on a downtime procedure before the study begins. It should identify who can authorize an alternative, how the site will protect participant privacy, how the consent discussion and documentation will be recorded, and how records will be reconciled with the electronic system afterward. Any alternative process should fit the protocol, applicable requirements, and approved study procedures; do not assume that an unapproved paper or offline workflow is automatically acceptable.
Finally, document an exit plan: how the sponsor can obtain complete records and audit trails, verify the export, transition to another system, and arrange continued access for the required retention period. A sound assessment brings together access controls, protected data flows, reliable audit trails, fit-for-purpose validation, and practical continuity arrangements.
FAQs
What security evidence should an eConsent platform vendor provide?
Ask for evidence relevant to the platform’s use in your study: system and data-flow descriptions, access-control procedures, security and incident-response summaries, validation documentation, audit-trail and record-export details, backup and recovery procedures, and available independent assessment reports. Review each item’s scope and date, and clarify any limitations, exceptions, or remediation items. Evidence supports your assessment; it does not establish that your organization or study is compliant by itself.
How can sponsors verify who can access consent records?
Request a role and permission matrix, a current authorized-user list for the study, and records showing how accounts are created, changed, reviewed, and removed. Confirm that user actions are attributable to unique accounts and that privileged or vendor support access is restricted and logged. FDA guidance recommends maintaining records of authorized users, their roles, and their permissions.
What should an eConsent audit trail record?
It should support reconstruction of important consent-record activity, including creation, changes, corrections, and deletion. Review whether entries identify the user, date and time, and prior and new values where applicable, and whether the reason for a change is captured when appropriate. The audit trail should be protected against alteration, remain linked to the record, and be retained with the associated records for the required period.
What happens to consent records if the platform becomes unavailable?
The vendor’s continuity plan should explain backup and recovery, outage communications, record restoration, and how affected activity is identified. Your study procedures should define whether and how an approved alternative consent process may be used during an outage, who authorizes it, and how records are reconciled afterward. Confirm that the sponsor can obtain and preserve complete consent records and audit trails if the service is unavailable or the contract ends.
Table of Contents
- Which vendor security controls should a clinical trial eConsent assessment cover?
- How should access controls and authentication be evaluated?
- How are consent records stored, transferred, and protected?
- What should audit trails capture and how should records be archived?
- What vendor documentation and system validation evidence should be requested?
- How should platform oversight, maintenance, and downtime alternatives be assessed?
- FAQs
Ready to assess your HIPAA security risks?
Join thousands of organizations that use Accountable to identify and fix their security gaps.
Take the Free Risk Assessment